Geron Corporation

geron.com

What Do They Do?

Sells RYTELO, a medicine for adults with certain lower-risk blood cancers, through drug distributors and specialty pharmacies.

Who Are Their Customers?

Geron sells RYTELO to third-party distributors and specialty pharmacies, which resell it through specialty pharmacies to patients and health care providers; government programs and insurers provide coverage and reimbursement.

Do Revenues Turn Into Profits?

No. It lost $83.5M in FY2025.

Operating income, FY2025

−37% of revenue

▼ −61% (Loss) vs FY2024 (−$173.7M, −226%)

Net income, FY2025

−45% of revenue

▼ −52% (Loss) vs FY2024 (−$174.6M, −227%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +17%; vs $49M in Q2 FY2025
Net income: ▲ +2% (Loss); vs −$16.4M in Q2 FY2025

Gross product revenue share of revenue vs 118.0% in Q2 FY2025

Aug 6, 2026 Reiterated RYTELO revenue and operating expense guidance The company reiterated ranges for 2026 RYTELO net product revenue and total operating expenses.

From development to sales Geron has moved from describing imetelstat as an investigational therapy and planning a possible U.S. launch after approval to selling RYTELO in the U.S.; it also has EU authorization and plans commercialization there with third parties.

Revenue over time

Revenues Before Adjustments Chargebacks Distributor service fees Government Rebates Sales Returns And Allowance Total Gross To Net Adjustments Product revenues, net License Fees And Royalties Member Royalties

$500M$250M$0

FY2022 FY2023 FY2024 FY2025

Comments